within Pharmacolibrary.Drugs.ATC.S;

model S01ED51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.013333333333333334,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Timolol is a non-selective beta-adrenergic antagonist primarily used for the reduction of intraocular pressure in the treatment of glaucoma. In the ATC group S01ED51, timolol is utilized in combination with other agents to enhance intraocular pressure-lowering efficacy. It is an approved medication and widely used in clinical ophthalmology today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for timolol in fixed-dose ophthalmic combinations in healthy adult patients, as specific PK profiles for combinations in published literature are limited. Based on pharmacokinetics of ophthalmic timolol exposures from referenced single-agent studies.</p><h4>References</h4><ol><li>Sheridan M Hoy, Susan J Keam, Gillian M Keating,Travoprost/timolol.,Drugs & aging,2006<a href='https://pubmed.ncbi.nlm.nih.gov/16930087/'>https://pubmed.ncbi.nlm.nih.gov/16930087/</a></li><li>Michael Herceg, Robert Noecker,Travoprost/timolol fixed combination.,Expert opinion on pharmacotherapy,2008<a href='https://pubmed.ncbi.nlm.nih.gov/18377347/'>https://pubmed.ncbi.nlm.nih.gov/18377347/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01ED51;
